Literature DB >> 21133822

Combination of low-dose aspirin and thienopyridine exacerbates small bowel injury.

Akiko Shiotani1, Keisuke Honda, Takahisa Murao, Manabu Ishii, Minoru Fujita, Hiroshi Matsumoto, Ken-ichi Tarumi, Tomoari Kamada, Takashi Sakakibara, Ken Haruma.   

Abstract

OBJECTIVE: Antithrombotics is increasingly being used for cardiovascular prevention. In more recent studies, small bowel injury and enteropathy associated with low-dose aspirin are increasingly being recognized. Aim of this study was to evaluate small bowel injury using video capsule endoscopy (VCE) in obscure gastrointestinal bleeding (OGIB) patients taking low-dose aspirin including other antithrombotics.
MATERIAL AND METHODS: This is a retrospective review of chronic users of antithrombotics who underwent VCE for suspected small bowel bleeding. Small bowel mucosal injury was evaluated using VCE findings.
RESULTS: Fifty-four OGIB patients (36 men and 18 women, mean age 72.4 years) underwent VCE from January 2007 to May 2009. Twenty-two patients were taking 100 mg of enteric-coated aspirin (aspirin group), 8 taking thienopyridine, (ticlopidine or clopidogrel, thienopyridine group), 13 taking aspirin combined with thienopyridine (combined group), and 11 taking warfarin (warfarin group). The mucosal injury, especially ulcers were most frequently detected in the combined group (46.2%, p = 0.01) among the four groups. The median number of redness lesions in the combined group was the highest among the four groups and was significantly higher than that in the warfarin group. The lesions of redness or small erosions in the aspirin and the combined groups tended to exist in the proximal part of small bowel.
CONCLUSIONS: Combination of low-dose aspirin therapy and thienopyridine may exacerbate small bowel injury, and the preventive strategies should be established.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21133822     DOI: 10.3109/00365521.2010.533381

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  11 in total

1.  Antithrombotic Treatment Is Associated with Small-Bowel Video Capsule Endoscopy Positive Findings in Obscure Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.

Authors:  Georgios Tziatzios; Paraskevas Gkolfakis; Ioannis S Papanikolaou; Konstantinos Triantafyllou
Journal:  Dig Dis Sci       Date:  2018-09-20       Impact factor: 3.199

2.  Clopidogrel IBS Patients Have Higher Incidence of Gastrointestinal Symptoms Influenced by Age and Gender.

Authors:  Suren Soghomonyan; Mahmoud Abdel-Rasoul; Alix Zuleta-Alarcon; Iveta Grants; Victor Davila; Jeffrey Yu; Cheng Zhang; Emmett E Whitaker; Sergio D Bergese; Nicoleta Stoicea; Razvan Arsenescu; Fievos L Christofi
Journal:  Dig Dis Sci       Date:  2017-08-24       Impact factor: 3.199

Review 3.  Small bowel injury in low-dose aspirin users.

Authors:  Hiroki Endo; Eiji Sakai; Takayuki Kato; Shotaro Umezawa; Takuma Higurashi; Hidenori Ohkubo; Atsushi Nakajima
Journal:  J Gastroenterol       Date:  2014-12-14       Impact factor: 7.527

4.  New evidence on the impact of antithrombotics in patients submitted to small bowel capsule endoscopy for the evaluation of obscure gastrointestinal bleeding.

Authors:  Pedro Boal Carvalho; Bruno Rosa; Maria João Moreira; José Cotter
Journal:  Gastroenterol Res Pract       Date:  2014-11-06       Impact factor: 2.260

5.  A Small Bowel Ulcer due to Clopidogrel with Cytomegalovirus Enteritis Diagnosed by Capsule and Double-Balloon Endoscopy.

Authors:  Masahide Ebi; Satoshi Inoue; Tomoya Sugiyama; Kazuhiro Yamamoto; Kazunori Adachi; Takashi Yoshimine; Yoshiharu Yamaguchi; Yasuhiro Tamura; Shinya Izawa; Yasutaka Hijikata; Yasushi Funaki; Naotaka Ogasawara; Makoto Sasaki; Kunio Kasugai
Journal:  Case Rep Gastroenterol       Date:  2018-06-18

6.  Acute Middle Gastrointestinal Bleeding Risk Associated with NSAIDs, Antithrombotic Drugs, and PPIs: A Multicenter Case-Control Study.

Authors:  Naoyoshi Nagata; Ryota Niikura; Atsuo Yamada; Toshiyuki Sakurai; Takuro Shimbo; Yuka Kobayashi; Makoto Okamoto; Yuzo Mitsuno; Keiji Ogura; Yoshihiro Hirata; Kazuma Fujimoto; Junichi Akiyama; Naomi Uemura; Kazuhiko Koike
Journal:  PLoS One       Date:  2016-03-15       Impact factor: 3.240

7.  Clinical outcome of patients with obscure gastrointestinal bleeding during antithrombotic drug therapy.

Authors:  Yoshiyasu Kono; Seiji Kawano; Yuki Okamoto; Yuka Obayashi; Yuki Baba; Hiroyuki Sakae; Makoto Abe; Tatsuhiro Gotoda; Toshihiro Inokuchi; Hiromitsu Kanzaki; Masaya Iwamuro; Yoshiro Kawahara; Hiroyuki Okada
Journal:  Therap Adv Gastroenterol       Date:  2018-01-14       Impact factor: 4.409

8.  Optimal antiplatelet therapy for prevention of gastrointestinal injury evaluated by ANKON magnetically controlled capsule endoscopy: Rationale and design of the OPT-PEACE trial.

Authors:  Yi Li; Xiaozeng Wang; Dan Bao; Zhuan Liao; Jing Li; Xiao Han; Heyang Wang; Kai Xu; Zhaoshen Li; Gregg W Stone; Yaling Han
Journal:  Am Heart J       Date:  2020-06-15       Impact factor: 4.749

9.  Dual antiplatelet therapy does not affect the incidence of low-dose aspirin-induced small intestinal mucosal injury in patients after percutaneous coronary intervention for coronary stenosis: a multicenter cross-sectional study.

Authors:  Azusa Hara; Kazuhiro Ota; Toshihisa Takeuchi; Yuichi Kojima; Yuki Hirata; Haruhiko Ozaki; Shinpei Kawaguchi; Yoshiaki Takahashi; Satoshi Harada; Taisuke Sakanaka; Takeshi Ogura; Sadaharu Nouda; Kazuki Kakimoto; Ken Kawakami; Akira Asai; Shinya Fukunishi; Makoto Sanomura; Kazunari Tominaga; Kazuhide Higuchi
Journal:  J Clin Biochem Nutr       Date:  2018-05-25       Impact factor: 3.114

10.  Usefulness of Ultrasonography for Diagnosis of Small Bowel Tumors: A Comparison Between Ultrasonography and Endoscopic Modalities.

Authors:  Minoru Fujita; Noriaki Manabe; Keisuke Honda; Takahisa Murao; Motoyasu Osawa; Ryosuke Kawai; Takashi Akiyama; Akiko Shiotani; Ken Haruma; Jiro Hata
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.